Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.
Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.
Plans to unwind the Suffern, NY, site move forward this winter.
Endo's timing also comes as Auxilium has committed to reorganizing and merging with Canada's QLT.
Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.
With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.
The plan is to bring in-house products to the market as well as through acquisitions.
Lilly's long-acting insulin showed it's more effective in type 1 diabetics than Lantus, but concerns about its overall profile persist.
Bloomberg reports that India's Wockhardt has become an M&A target.
Pfizer will sell two Novartis drugs in the UK.
Sales reps are among the pinked-slipped in Spain.
The FDA has approved Arnuity Ellipta for asthma.
Amgen now hopes a separate study will be enough to support the drug's advancement to a second-line therapy, but the lackluster results may impinge on its EU filing schedule.
GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.
Layoffs are reported to be in the offing.
Blood-cancer drug Kyprolis outperformed standard treatment in a late-stage trial testing the drug in patients with multiple myeloma, said Amgen.
Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.
The meningitis and encephalitis medications earned a combined $300 million last year.
AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.
The majority of the layoffs will be in the US.
Patent losses and lost co-promotion agreements put a dent in sales.
The company refutes a Financial Times rumor that one was happening soonish.
Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?
The drug did not hit its Phase III primary target of improving progression-free survival.
Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.
A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.
Executives urge analysts to focus on the company's long-term potential.
CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.
Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.